MedTrace Logo

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2014-04-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.

Conditions

Interventions

DRUG

Lurasidone 20 mg

Lurasidone 20mg oral tablet taken once daily for 6-months

DRUG

Lurasidone 40 mg

Lurasidone 40mg oral tablets taken once daily

DRUG

Lurasidone 80mg

Lurasidone 80mg oral tablet taken once daily

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director, MD · Sumitomo Pharma America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044005 on ClinicalTrials.gov